Inhibitors of the monocyte chemoattractant protein 1 (MCP-1/CCR2) pathway, for instance, have been shown to attenuate insulin resistance and other negative consequences of excessive energy intake in laboratory rodents [12]–[14]. The gene discussed is CCL2; the disease is Insulin resistance.